| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |